PD-1/PD-L1抑制剂与前列腺癌免疫治疗的研究进展  

Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer

作　　者：黄林(综述) 何娟(审校)[3] HUANG Lin;HE Juan(Department of Urology,Tumor Hospital Affiliated to Guangxi Medical University,Nanning Guangxi 530021,China;Department of Urology,The Fourth Affiliated Hospital of Guangxi Medical University,Liuzhou,Guangxi 545005,China;Department of Pathology,The Fourth Affiliated Hospital of Guangxi Medical University,Liuzhou,Guangxi 545005,China)

机构地区：[1]广西医科大学附属肿瘤医院泌尿外科,广西南宁530021 [2]广西医科大学第四附属医院,泌尿外科,广西柳州545005 [3]广西医科大学第四附属医院病理科,广西柳州545005

出　　处：《中华男科学杂志》2020年第10期944-948,共5页National Journal of Andrology

基　　金：广西壮族自治区卫生和计划生育委员会科研课题(Z20180483);广西医科大学青年科学基金资助课题(GXMUYSF201708)。

摘　　要：前列腺癌已成为老年男性常见恶性疾病之一,发病率呈逐年上升趋势。目前,在前列腺癌的肿瘤免疫治疗领域,以程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)抑制剂为代表的免疫疗法是继外科、放疗、化疗之后最具有研究前景的新型治疗方法。PD-1/PD-L1抑制剂主要通过阻断肿瘤细胞PD-1/PD-L1信号通路,恢复T细胞的活性,扭转肿瘤免疫逃逸机制,让免疫系统得以恢复从而直接杀死肿瘤细胞。本文就目前PD-1/PD-L1抑制剂与前列腺癌相关的研究进展进行综述。Prostate cancer(PCa) has become one of the common malignant diseases in elderly men, and its incidence is increasing year by year. Apart from surgery, radiotherapy and chemotherapy, immunotherapy, as with the programmed death receptor-1(PD-1) or the programmed death ligand-1(PD-L1) inhibitor, is a most promising new strategy for the treatment of PCa. PD-1 and PD-L1 inhibitors restore the activity of T cells by blocking the PD-1/PD-L1 signaling pathway in tumor cells, reverse the mechanism of tumor immune escape, recover the immune system and directly kill tumor cells. This review focuses on the current progress in the studies of PD-1 and PD-L1 inhibitors in the treatment of PCa. Natl J Androl, 2020, 26(10): 944-948.

关 键 词：程序性死亡受体1/程序性死亡配体1 前列腺癌 免疫治疗 

分 类 号：R737.25[医药卫生—肿瘤]